Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?

Benzinga03-30

The filing also asks shareholders to approve a new 2026 Stock Incentive Plan, which the company said is intended to support recruiting, retention and performance goals. That filing may be pressuring ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623434297?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/30/Financial-Market-Crash-Concept-With-Red-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-03-30 23:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623434297","market":"hk","top_or_hot":-1,"title":"Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?","media":"Benzinga","content":"<div>\n<p>The filing also asks shareholders to approve a new 2026 Stock Incentive Plan, which the company said is intended to support recruiting, retention and performance goals.\nThat filing may be pressuring ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51543853/tonix-pharmaceuticals-stock-hits-new-52-week-low-whats-driving-the-action\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-30 23:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/03/51543853/tonix-pharmaceuticals-stock-hits-new-52-week-low-whats-driving-the-action><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The filing also asks shareholders to approve a new 2026 Stock Incentive Plan, which the company said is intended to support recruiting, retention and performance goals.\nThat filing may be pressuring ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51543853/tonix-pharmaceuticals-stock-hits-new-52-week-low-whats-driving-the-action\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNXP","symbol_name":"Tonix Pharmaceuticals Holding Co","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51543853/tonix-pharmaceuticals-stock-hits-new-52-week-low-whats-driving-the-action","article_id":"2623434297","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/30/Financial-Market-Crash-Concept-With-Red-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51543853/tonix-pharmaceuticals-stock-hits-new-52-week-low-whats-driving-the-action","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623434297","pubTimestamp":1774885380,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from late last week.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNXP":"Tonix Pharmaceuticals Holding Co","BK4150":"赌场与赌博","BK4583":"猴痘概念","RSI":"Rush Street Interactive, Inc.","BK4139":"生物科技"},"translate_title":"Tonix Pharmaceuticals股价创52周新低：是什么推动了这一走势？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RSI":1,"TNXP":1.5},"content_text":"The filing also asks shareholders to approve a new 2026 Stock Incentive Plan, which the company said is intended to support recruiting, retention and performance goals.\nThat filing may be pressuring sentiment because reverse split proposals often signal efforts to maintain listing compliance and can amplify investor concerns around dilution and prolonged share-price weakness.\nLast Thursday, Tonix announced the first participant had been dosed in a Phase 1 investigator-initiated study of TNX-1900, its intranasal potentiated oxytocin candidate for migraine and craniofacial pain. \nThe company said the study will evaluate trigeminal nerve-mediated vasodilation and highlighted TNX-1900's mechanism as distinct from existing CGRP-targeting migraine therapies.\nOver the past year, Tonix Pharmaceuticals’ (TNXP) Relative Strength Index (RSI) displayed significant volatility, repeatedly surging into overbought territory above 70 during the first half of the period. \nMore recently, the stock’s momentum has cooled considerably, briefly touching oversold levels before stabilizing in the lower-neutral zone by late March 2026.\nTNXP Price Action: Tonix Pharmaceuticals shares were down 5.51% at $12.18 at the time of publication on Monday. The stock is trading at a new 52-week low, according to Benzinga Pro data.\nImage: Adobe Stock Images\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623434297","isCrawlerRequest":true}